AbCellera Biologics Inc.
ABCL
$10.97
$0.625.94%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 66.17M | 79.21M | 75.13M | 35.32M | 32.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.17M | 79.21M | 75.13M | 35.32M | 32.88M |
| Cost of Revenue | 197.77M | 191.00M | 186.83M | 182.81M | 168.75M |
| Gross Profit | -131.60M | -111.79M | -111.70M | -147.49M | -135.88M |
| SG&A Expenses | 68.36M | 76.50M | 83.23M | 85.18M | 82.50M |
| Depreciation & Amortization | 25.20M | 23.68M | 22.17M | -3.39M | 28.29M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 291.33M | 291.17M | 292.23M | 264.60M | 279.54M |
| Operating Income | -225.16M | -211.96M | -217.11M | -229.28M | -246.66M |
| Income Before Tax | -196.77M | -174.15M | -177.60M | -204.93M | -198.79M |
| Income Tax Expenses | -32.11M | -30.19M | -31.18M | -33.25M | -33.12M |
| Earnings from Continuing Operations | -164.66 | -143.96 | -146.41 | -171.68 | -165.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -164.66M | -143.96M | -146.41M | -171.68M | -165.67M |
| EBIT | -225.16M | -211.96M | -217.11M | -229.28M | -246.66M |
| EBITDA | -199.96M | -188.29M | -194.93M | -198.52M | -184.23M |
| EPS Basic | -0.54 | -0.48 | -0.49 | -0.58 | -0.56 |
| Normalized Basic EPS | -0.41 | -0.36 | -0.37 | -0.40 | -0.42 |
| EPS Diluted | -0.55 | -0.48 | -0.49 | -0.58 | -0.56 |
| Normalized Diluted EPS | -0.41 | -0.36 | -0.37 | -0.40 | -0.42 |
| Average Basic Shares Outstanding | 1.21B | 1.20B | 1.19B | 1.19B | 1.19B |
| Average Diluted Shares Outstanding | 1.21B | 1.20B | 1.19B | 1.19B | 1.19B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |